Idexx Laboratories Surges 27.49% on $2.24B Volume Ranks 25th in Market Activity as Diagnostic Demand and New Product Launches Fuel Earnings Beat

Idexx Laboratories (IDXX) surged 27.49% on August 4, 2025, with a trading volume of $2.24 billion—a 450.78% increase from the previous day—ranking it 25th in market activity. The stock’s rally followed robust second-quarter results, driven by strong demand for veterinary diagnostics and new product launches.

The Maine-based company reported $1.11 billion in revenue, exceeding estimates of $1.07 billion, while adjusted earnings per share reached $3.63, surpassing forecasts of $3.30. Analysts highlighted the “puppy boom” of 2020 as a key growth catalyst, with aging pets increasing demand for diagnostic services. Idexx also introduced the inVue Dx analyzer in late 2024, which processes blood and ear samples, further diversifying its offerings.

William Blair analyst Ryan Daniels noted resilience in the pet health sector despite slower veterinary visits. Idexx raised its annual sales guidance to $4.205 billion–$4.28 billion, reflecting strong recurring revenue from diagnostic services. Foreign exchange benefits and higher adoption of the inVue Dx product were cited as additional tailwinds.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.